Company intelligence / Profile preview
IFM Due
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
IFM Due developed small molecule, orally available cGAS-STING pathway antagonists for serious inflammatory and autoimmune diseases; assets remained preclinical at the time of Novartis acquisition, with no public clinical data disclosed.[2][3][6]
- Therapeutic areas
- ImmunologyRare DiseasesPulmonology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Novartis (acquired after exclusive option partnership)
Beyond the preview
Go deeper on IFM Due.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFM Due.